Mesangiolysis and/or mesangial cell proliferation are involved in the pathogenesis of several glomerular disease states in humans. The long-term goals of this project are to analyze the mechanistic events underlying these phenomena, particularly in terms of growth regulation of glomerular cells, cell-cell interactions and cell-matrix interactions. It has been found that heparin profoundly inhibits mesangial cell proliferation in vitro and in vivo. Heparin-like species also inhibit vascular smooth muscle cell proliferation, but there are differences and similarities in the responses of these two cell types. It will be established whether non-anticoagulant, (particularly antithrombotic), heparin-like species have similar effects. As in vivo, simple mesangial cell proliferative systems, the Habu snake venom, and nickel subsulfide, models will be used. The latter is also characterized by erythrocytosis. Mesangial cells are thought to produce erythropoietin. The effects of heparin-like species in these regards will also be studied, both in vivo and in vitro. Conditioned media from glomerular epithelial cells inhibit mesangial cell proliferation. Endothelial cells produce both inhibitory and stimulatory activities. These activities will be characterized, particularly as to whether the inhibitory activities represent heparin-like species. The mechanisms of mesangiolysis in the Habu snake venom model will be studied to establish whether the primary injury is cellular, or is on the mesangial matrix. If the latter, the interactions between the matrix and mesangial cells, in terms of cellular integrity will be investigated. The aminonucleoside of puromycin effects glomerular epithelial cells, both in vitro and in vivo, in the latter case producing a proteinuria and a lesion similar to lipoid nephrosis in children. Protective effects against the aminonucleoside have been found in vitro with various carbohydrate compounds, including heparin. Protection will be further characterized, particularly in regard to cell-matrix interaction mechanisms, and role of oxygen-free radicals in producing the lesion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
2R01AM013132-16A1
Application #
3150847
Study Section
Pathology A Study Section (PTHA)
Project Start
1975-10-01
Project End
1990-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
16
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
Diamond, J R (1992) The role of reactive oxygen species in animal models of glomerular disease. Am J Kidney Dis 19:292-300
Diamond, J R (1991) Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 31:S29-34
Diamond, J R; Hanchak, N A; McCarter, M D et al. (1990) Cholestyramine resin ameliorates chronic aminonucleoside nephrosis. Am J Clin Nutr 51:606-11
Diamond, J R (1990) Effects of dietary interventions on glomerular pathophysiology. Am J Physiol 258:F1-8
Rosenblum, N D; Karnovsky, M J; Olsen, B R (1990) Non-fibrillar collagenous proteins synthesized by rat mesangial cells. J Am Soc Nephrol 1:785-91
Diamond, J R; Pesek, I; McCarter, M D et al. (1989) Altered functional characteristics of rat macrophages during nephrosis. Synergistic effects of hypercholesterolemia. Am J Pathol 135:711-8
Diamond, J R; Pesek, I; Ruggieri, S et al. (1989) Essential fatty acid deficiency during acute puromycin nephrosis ameliorates late renal injury. Am J Physiol 257:F798-807
Kon, V; Karnovsky, M J (1989) Morphologic demonstration of adrenergic influences on the glomerulus. Am J Pathol 134:1039-46
Diamond, J R; Karnovsky, M J (1988) Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33:917-24
Anderson, S; Diamond, J R; Karnovsky, M J et al. (1988) Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757-68

Showing the most recent 10 out of 19 publications